---
title: Align Technology (ALGN) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/algn
ticker: ALGN
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Devices
---
# Align Technology (ALGN)

Align Technology (ALGN) closed at $147.31 on Oct 16, 2026, overvalued by 103% vs its model value of $72.43 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $147.31 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $72.43 |
| Price vs model | overvalued by 103% vs model |
| Range of that model | $58.70 – $102.15 |
| Market value | $10.5B |
| P/E (fiscal 2025) | 26.1 |
| Net margin (fiscal 2025) | 10.2% |
| Free cash flow (fiscal 2025) | $490.8M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 1.67 |
| Cost of capital (WACC) | 11.10% |
| Business classification | Mature & Stable (Low/slowing growth (~2% recent), Moderate margins (10% net margin), Highly cyclical earnings) |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $72.43 | $58.70 | $102.15 |
| DCF · Perpetuity growth · 10y | cross check | $76.86 | $62.88 | $106.43 |
| DCF · EBITDA exit · 5y | cross check | $167.68 | $128.18 | $213.93 |
| DCF · EBITDA exit · 10y | cross check | $144.95 | $108.39 | $193.23 |
| P/E · peers | cross check | $341.21 | $244.09 | $438.32 |
| P/E · own history | cross check | $294.84 | $239.65 | $412.02 |
| PEG | sanity check | $281.53 | $281.53 | $281.53 |
| EV/EBITDA · peers | cross check | $209.34 | $147.03 | $271.65 |
| EV/Revenue · peers | cross check | $121.75 | $89.64 | $330.19 |
| Earnings power value | cross check | $81.13 | $73.27 | $91.45 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

No open-market insider buys or sales filed in the past 90 days.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Aug 27, 2026 | Blackford Quentin S. | Director | Grant / award | 1,376 | $0 |
| May 20, 2026 | Vitalone Britt J. | Director | Option/RSU exercise | 1,443 | $0 |
| May 20, 2026 | Vitalone Britt J. | Director | Option/RSU exercise | 1,443 | $0 |
| May 20, 2026 | Vitalone Britt J. | Director | Grant / award | 1,836 | $0 |
| May 20, 2026 | SIEGEL SUSAN E | Director | Option/RSU exercise | 1,745 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 31, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1097149/000109714926000065/algn-20260827.htm |
| Aug 5, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1097149/000109714926000060/algn-20260630.htm |
| Jul 29, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1097149/000109714926000056/algn-20260729.htm |
| Jul 29, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1097149/000109714926000054/algn-20260729.htm |
| Jul 9, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/1097149/000109714926000050/algn-20260706.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Ruane Cunniff | 2026-06-30 | 1,171,455 | $197.6M |
| Bridgewater | 2026-06-30 | 82,400 | $13.9M |

2 tracked managers in all.

## About

Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to…

---

Source: https://sweetvaluelab.com/stocks/algn (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.